BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Penn Epigenetics - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Penn Epigenetics
X-ORIGINAL-URL:https://epigenetics.upenndev.pendari.com
X-WR-CALDESC:Events for Penn Epigenetics
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260501T150000
DTEND;TZID=America/New_York:20260501T170000
DTSTAMP:20260424T143412Z
CREATED:20260424T143412Z
LAST-MODIFIED:20260424T143412Z
UID:14332-1777647600-1777654800@epigenetics.upenndev.pendari.com
SUMMARY:Special Seminar featuring Prof. Sir Tony Kouzarides
DESCRIPTION:Please join us for a Special Seminar featuring Prof. Sir Tony Kouzarides on Friday\, May 1\, 2026\, at 3PM in the KRB (formerly BRB) Gaulton Auditorium. Following the event\, we hope you will stay for a reception in the KRB Lobby! \nAll are welcome to attend. Please share with your colleagues and let us know if you plan to join us by registering here: https://bit.ly/4t3rAOf. \n“Maximising Impact: lessons from a career in academic research and startups” \nA journey from pioneering research in epigenetics to globally impactful startups. The story of the founding of Abcam\, a billion-dollar antibody reagents company and Storm Therapeutics\, a drug discovery company translating a target from the lab into patient treatment against cancer. The setting up of PRIMED\, a new entrepreneurial organisation will be presented. PRIMED will help early career scientist understand the process of startup creation and promote those with ideas towards founding startups. \nAbout Prof. Sir Tony Kouzarides\, PhD\, FRS\, FMedSci \nSir Tony is a professor of Cancer Biology at the University of Cambridge\, and a pioneer of the epigenetics field. He is founder and director of the Milner Therapeutics Institute\, whose mission is to connect academia and industry to develop new therapies. A serial entrepreneur\, he has founded several companies including Abcam and Storm Therapeutics. His most recent company\, VELLOS\, is setting up a new entrepreneurial program called PRIMED in Europe and the US\, to promote startup creation by early career scientists. He is a venture partner in the San Francisco Investor firm Fifty Years. He was knighted by the King for “Services to Healthcare Innovation and Delivery”.
URL:https://epigenetics.upenndev.pendari.com/event/special-seminar-featuring-prof-sir-tony-kouzarides/
ATTACH;FMTTYPE=image/jpeg:https://epigenetics.upenndev.pendari.com/wp-content/uploads/2026/04/tony.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260501T150000
DTEND;TZID=America/New_York:20260501T170000
DTSTAMP:20260424T143412Z
CREATED:20260424T143412Z
LAST-MODIFIED:20260424T143412Z
UID:14805-1777647600-1777654800@epigenetics.upenndev.pendari.com
SUMMARY:Special Seminar featuring Prof. Sir Tony Kouzarides
DESCRIPTION:Please join us for a Special Seminar featuring Prof. Sir Tony Kouzarides on Friday\, May 1\, 2026\, at 3PM in the KRB (formerly BRB) Gaulton Auditorium. Following the event\, we hope you will stay for a reception in the KRB Lobby! \nAll are welcome to attend. Please share with your colleagues and let us know if you plan to join us by registering here: https://bit.ly/4t3rAOf. \n“Maximising Impact: lessons from a career in academic research and startups” \nA journey from pioneering research in epigenetics to globally impactful startups. The story of the founding of Abcam\, a billion-dollar antibody reagents company and Storm Therapeutics\, a drug discovery company translating a target from the lab into patient treatment against cancer. The setting up of PRIMED\, a new entrepreneurial organisation will be presented. PRIMED will help early career scientist understand the process of startup creation and promote those with ideas towards founding startups. \nAbout Prof. Sir Tony Kouzarides\, PhD\, FRS\, FMedSci \nSir Tony is a professor of Cancer Biology at the University of Cambridge\, and a pioneer of the epigenetics field. He is founder and director of the Milner Therapeutics Institute\, whose mission is to connect academia and industry to develop new therapies. A serial entrepreneur\, he has founded several companies including Abcam and Storm Therapeutics. His most recent company\, VELLOS\, is setting up a new entrepreneurial program called PRIMED in Europe and the US\, to promote startup creation by early career scientists. He is a venture partner in the San Francisco Investor firm Fifty Years. He was knighted by the King for “Services to Healthcare Innovation and Delivery”.
URL:https://epigenetics.upenndev.pendari.com/event/special-seminar-featuring-prof-sir-tony-kouzarides-2/
ATTACH;FMTTYPE=image/jpeg:https://epigenetics.upenndev.pendari.com/wp-content/uploads/2026/04/tony.jpg
END:VEVENT
END:VCALENDAR